What is the price of Sunlenca in China?

Lenapavir sodium/Sunlenca (Sunlenca) is a new antiviral drug that has attracted widespread attention in recent years. It is the first long-acting HIV capsid inhibitor in the treatment of HIV-1. Unlike traditional daily oral antiretroviral drugs, lenapavir sodium can significantly delay the viral replication cycle by blocking the key steps of the viral capsid. Therefore, it is regarded as an important breakthrough in the treatment of chronic HIV (AIDS) in clinical application. Its advantage lies not only in the novelty of the drug mechanism but also in its unique delivery method.

Lenapavir sodium is currently available in dual dosage forms of oral tablets and subcutaneous injections in China, allowing patients to choose based on clinical conditions. In particular, the long-acting properties of injections can extend the medication interval to about half a year, which brings new hope to many patients who have long been dependent on drugs.

In terms of price, since lenapavir sodium has just entered the domestic market, its selling price is not yet completely transparent, and it has not yet been included in the medical insurance catalog. Under normal circumstances, new antiviral original research drugs are often more expensive in the early stages and have limited supply channels. Based on overseas market data, the prices of the American and European versions of lenapavir sodium are among the high-end drugs. Domestic pricing may refer to this international range. However, as the country's price negotiation mechanism for innovative drugs gradually matures, its market price may still be significantly adjusted in the future.

In the current clinical environment in China, patients' access to napavir sodium mainly relies on the imported drug supply chain of some hospitals, and ordinary pharmacies or online channels are not yet popular. Therefore, in the short term, the accessibility of lenapavir sodium remains an important factor affecting its application and promotion.

As the global HIV prevention and control strategy gradually shifts to long-term management and high-compliance treatment, lenapavir sodium is expected to gradually expand its affordability and coverage in the country in the next few years. Once price negotiations are completed and included in medical insurance, its application is expected to grow rapidly.

Reference materials:https://www.drugs.com/sunlenca.html